γ‑tocotrienol prevents 5‑FU‑induced reactive oxygen species production in human oral keratinocytes through the stabilization of 5‑FU‑induced activation of Nrf2

Takano,Hideyuki; Momota,Yukihiro; Kani,Kouichi; Aota,Keiko; Yamamura,Yoshiko; Yamanoi,Tomoko; Azuma,Masayuki

doi:10.3892/ijo.2015.2849

γ‑tocotrienol prevents 5‑FU‑induced reactive oxygen species production in human oral keratinocytes through the stabilization of 5‑FU‑induced activation of Nrf2

Authors:
- Hideyuki Takano
- Yukihiro Momota
- Kouichi Kani
- Keiko Aota
- Yoshiko Yamamura
- Tomoko Yamanoi
- Masayuki Azuma
View Affiliations

Affiliations: Department of Oral Medicine, Institute of Health Biosciences, The University of Tokushima Graduate Faculty of Dentistry, Tokushima, Japan
Published online on: January 26, 2015 https://doi.org/10.3892/ijo.2015.2849
Pages: 1453-1460
Copyright: © Takano et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemotherapy‑induced oral mucositis is a common adverse event in patients with oral squamous cell carcinoma, and is initiated through a variety of mechanisms, including the generation of reactive oxygen species (ROS). In this study, we examined the preventive effect of γ‑tocotrienol on the 5‑FU‑induced ROS production in human oral keratinocytes (RT7). We treated RT7 cells with 5‑FU and γ‑tocotrienol at concentrations of 10 µg/ml and 10 nM, respectively. When cells were treated with 5‑FU alone, significant growth inhibition was observed as compared to untreated cells. This inhibition was, in part, due to the ROS generated by 5‑FU treatment, because N‑acetyl cysteine (NAC), a ROS scavenger, significantly ameliorated the growth of RT7 cells. γ‑tocotrienol showed no cytotoxic effect on the growth of RT7 cells. Simultaneous treatment of cells with these agents resulted in the significant recovery of cell growth, owing to the suppression of ROS generation by γ‑tocotrienol. Whereas 5‑FU stimulated the expression of NF‑E2‑related factor 2 (Nrf2) protein in the nucleus up to 12 h after treatment of RT7 cells, γ‑tocotrienol had no obvious effect on the expression of nuclear Nrf2 protein. Of note, the combined treatment with both agents stabilized the 5‑FU‑induced nuclear Nrf2 protein expression until 24 h after treatment. In addition, expression of Nrf2‑dependent antioxidant genes, such as heme oxygenase‑1 (HO‑1) and NAD(P)H:quinone oxidoreductase‑1 (NQO‑1), was significantly augmented by treatment of cells with both agents. These findings suggest that γ‑tocotrienol could prevent 5‑FU‑induced ROS generation by stabilizing Nrf2 activation, thereby leading to ROS detoxification and cell survival in human oral keratinocytes.

View Figures

View References

1	Keefe DM, Schubert MM, Elting LS, et al: Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 109:820–831. 2007. View Article : Google Scholar : PubMed/NCBI
2	Le QT, Kim HE, Schneider CJ, et al: Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol. 29:2808–2814. 2011. View Article : Google Scholar : PubMed/NCBI
3	Sonis ST: The pathobiology of mucositis. Nat Rev Cancer. 4:277–284. 2004. View Article : Google Scholar : PubMed/NCBI
4	Bloomer WD and Hellman S: Normal tissue responses to radiation therapy. N Engl J Med. 293:80–83. 1975. View Article : Google Scholar : PubMed/NCBI
5	Lockhart PB and Sonis ST: Relationship of oral complications to peripheral blood leukocyte and platelet counts in patients receiving cancer chemotherapy. Oral Surg Oral Med Oral Pathol. 48:21–28. 1971. View Article : Google Scholar
6	Sonis ST, Lindquist L, Van Vugt A, et al: Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3. Cancer Res. 54:1135–1138. 1994.PubMed/NCBI
7	Henke M, Alfonsi M, Foa P, et al: Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol. 29:2815–2820. 2011. View Article : Google Scholar : PubMed/NCBI
8	Sonis ST: Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 34:39–43. 1998. View Article : Google Scholar : PubMed/NCBI
9	Sonis ST, Peterson RL, Edwards LJ, et al: Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol. 36:373–381. 2000. View Article : Google Scholar : PubMed/NCBI
10	Paris F, Fuks Z, Kang A, et al: Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 293:293–297. 2001. View Article : Google Scholar : PubMed/NCBI
11	Kinhult S, Albertsson M, Eskilsson J and Cwikiel M: Effects of probucol on endothelial damage by 5-fluorouracil. Acta Oncol. 42:304–308. 2003. View Article : Google Scholar : PubMed/NCBI
12	Kuenen BC, Levi M, Meijers JC, et al: Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol. 21:2192–2198. 2003. View Article : Google Scholar : PubMed/NCBI
13	Nogueira V and Hay N: Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clin Cancer Res. 19:4309–4314. 2013. View Article : Google Scholar : PubMed/NCBI
14	Boonstra J and Post JA: Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene. 337:1–13. 2004. View Article : Google Scholar : PubMed/NCBI
15	Schafer FQ and Buettner GR: Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med. 30:1191–1212. 2001. View Article : Google Scholar : PubMed/NCBI
16	Perry G, Raina AK, Nunomura A, Wataya T, Sayre LM and Smith MA: How important is oxidative damage? Lessons from Alzheimer’s disease. Free Radic Biol Med. 28:831–834. 2000. View Article : Google Scholar : PubMed/NCBI
17	Toyokuni S, Okamoto K, Yodoi J and Hiai H: Persistent oxidative stress in cancer. FEBS Lett. 358:1–3. 1995. View Article : Google Scholar : PubMed/NCBI
18	Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 8:579–591. 2009. View Article : Google Scholar : PubMed/NCBI
19	Kensler TW, Wakabayashi N and Biswal S: Cell survival responses to environmental stresses via Keap1–2-ARE pathway. Annu Rev Pharmacol Toxicol. 47:89–116. 2007. View Article : Google Scholar
20	Yates MS, Tauchi M, Katsuoka F, et al: Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther. 6:154–162. 2007. View Article : Google Scholar : PubMed/NCBI
21	MacLeod AK, McMahon M, Plummer SM, et al: Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis. 30:1571–1580. 2009. View Article : Google Scholar : PubMed/NCBI
22	Hui KF, Lam BH, Ho DN, Tsao SW and Ching AK: Borte-zomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. Mol Cancer Res. 12:747–758. 2013.
23	Wada S: Cancer preventive effects of vitamin E. Curr Pharm Biotechnol. 13:156–164. 2012. View Article : Google Scholar
24	Kamal-Eldin A and Appelqvist LA: The chemistry and anti-oxidant properties of tocopherols and tocotrienols. Lipids. 31:671–701. 1996. View Article : Google Scholar : PubMed/NCBI
25	Kani K, Momota Y, Harada M, et al: γ-tocotrienol enhances the chemosensitivity of human oral cancer cells to docetaxel through the downregulation of the expression of NF-κB-regulated anti-apoptotic gene products. Int J Oncol. 42:75–82. 2013.
26	Wada S, Satomi Y, Murakoshi M, Noguchi N, Yoshikawa T and Nishino H: Tumor suppressive effects of tocotrienol in vivo and in vitro. Cancer Lett. 229:181–191. 2005. View Article : Google Scholar : PubMed/NCBI
27	Fujimoto R, Kamata N, Yokoyama K, et al: Establishment of immortalized human oral keratinocytes by gene transfer of a telomerase component. J Jpn Oral Muco Membr. 8:1–8. 2002.(In Japanese). View Article : Google Scholar
28	Tamatani T, Azuma M, Aota K, Yamashita T, Bando T and Sato M: Enhanced IkappaB kinase activity is responsible for the augmented activity of NF-kappaB in human head and neck carcinoma cells. Cancer Lett. 171:165–172. 2001. View Article : Google Scholar : PubMed/NCBI
29	McDonald JT, Kim K, Norris AJ, et al: Ionizing radiation activates the Nrf2 antioxidant response. Cancer Res. 70:8886–8895. 2010. View Article : Google Scholar : PubMed/NCBI
30	Imbert V, Rupec RA, Livolsi A, et al: Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell. 86:787–798. 1996. View Article : Google Scholar : PubMed/NCBI
31	DeNicola GM, Karreth FA, Humpton TJ, et al: Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 475:106–109. 2011. View Article : Google Scholar : PubMed/NCBI
32	Peterman A, Cella D, Glandon G, et al: Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Cancer Inst Monogr. 29:45–51. 2001. View Article : Google Scholar : PubMed/NCBI
33	Elting LS, Cooksley CD, Chambers MS and Garden AS: Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 68:1110–1120. 2007. View Article : Google Scholar : PubMed/NCBI
34	Koukourakis MI: Amifostine in clinical oncology: current use and future applications. Anticancer Drugs. 13:181–209. 2002. View Article : Google Scholar : PubMed/NCBI
35	Criswell T, Leskov K, Miyamoto S, Luo G and Boothman DA: Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene. 22:5813–5827. 2003. View Article : Google Scholar : PubMed/NCBI
36	Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell. 103:239–252. 2000. View Article : Google Scholar : PubMed/NCBI
37	Braun S, Hanselmann C, Gassmann MG, et al: Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol. 22:5492–5505. 2002. View Article : Google Scholar : PubMed/NCBI
38	Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI
39	Zhang DD: Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev. 38:769–789. 2006. View Article : Google Scholar : PubMed/NCBI
40	Furukawa M and Xiong Y: BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol. 25:162–171. 2005. View Article : Google Scholar :
41	Jiang T, Chen N, Zhao F, et al: High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 70:5486–5496. 2010. View Article : Google Scholar : PubMed/NCBI